It was recently reported that IL-1 inhibition, but not IL-6 inhibition, was associated with a 55% reduction in mortality risk in patients with severe COVID-19 who presented with respiratory insufficiency and hyper inflammation. This evidence concerns the gene IL1A and COVID-19.